Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$15.56 USD
-0.55 (-3.41%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $15.55 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Company Summary
Based in South San Francisco, Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases.
The company has three late-stage development programs: tividenofusp alfa (DNL310, ETV:IDS) for mucopolysaccharidosis II ("MPS II", or "Hunter syndrome"); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (“ALS”).
Other candidate include - SAR443820/DNL788 (RIPK1 inhibitor) which is currently being evaluated in ...
Company Summary
Based in South San Francisco, Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases.
The company has three late-stage development programs: tividenofusp alfa (DNL310, ETV:IDS) for mucopolysaccharidosis II ("MPS II", or "Hunter syndrome"); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (“ALS”).
Other candidate include - SAR443820/DNL788 (RIPK1 inhibitor) which is currently being evaluated in a phase II study for multiple sclerosis (MS), TAK-594/DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN) and DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome).
The company is evaluating a phase II study of eclitasertib (SAR443122/DNL758) (peripheral RIPK1 inhibitor) for cutaneous lupus erythematosus (CLE) and ulcerative colitis (UC).
In June 2023, Denali and Biogen announced plans to revise the clinical development program for BIIB122/DNL151 based on a review of portfolio timelines and resource prioritization. In August, Denali and Biogen amended their agreement whereby certain milestone criteria were changed while the total amount of development, regulatory and commercial milestones across all indications remains the same.
Denali also has a collaboration and option agreement with Takeda Pharmaceutical Company Limited, whereby it granted Takeda an option to develop and commercialize certain biologic products that are enabled by Denali’s delivery technology and intended for the treatment of neurodegenerative disorders. The company has collaborated with Sanofi on the development of small molecules that inhibit RIPK1, a critical signaling protein in the tumor necrosis factor (TNF) receptor pathway and a regulator of inflammation and cell death.
The company does not generate any revenues from product sales. It earned collaboration revenues of $330.5 million in 2023, a significant year-over-year rise from the year-ago figure of $108.5 million.
General Information
Denali Therapeutics Inc
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-866-8548
Fax: NA
Web: http://www.denalitherapeutics.com
Email: hansen@dnli.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.67 |
Current Year EPS Consensus Estimate | -2.61 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 16.11 |
52 Week High | 33.31 |
52 Week Low | 15.45 |
Beta | 1.33 |
20 Day Moving Average | 1,066,849.62 |
Target Price Consensus | 40.60 |
4 Week | -18.96 |
12 Week | -3.59 |
YTD | -24.93 |
4 Week | -16.56 |
12 Week | -10.63 |
YTD | -29.07 |
Shares Outstanding (millions) | 142.54 |
Market Capitalization (millions) | 2,296.31 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -14.67% |
vs. Previous Quarter | -19.44% |
vs. Previous Year | -64.40% |
vs. Previous Quarter | -99.57% |
Price/Book | 2.17 |
Price/Cash Flow | NA |
Price / Sales | 6.74 |
3/31/24 | NA |
12/31/23 | -13.50 |
9/30/23 | -11.54 |
3/31/24 | NA |
12/31/23 | -11.38 |
9/30/23 | -9.20 |
3/31/24 | NA |
12/31/23 | 13.65 |
9/30/23 | 16.06 |
3/31/24 | NA |
12/31/23 | 13.65 |
9/30/23 | 16.06 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -36.51 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | -36.51 |
3/31/24 | NA |
12/31/23 | -43.93 |
9/30/23 | -36.51 |
3/31/24 | NA |
12/31/23 | 7.42 |
9/30/23 | 8.09 |
3/31/24 | NA |
12/31/23 | NA |
9/30/23 | NA |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |